Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolZeljko Reiner, Garen Manvelian, Robert Pordy et al.|Journal of the American College of Cardiology|2021Cited by 143
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab TreatmentGregory G. Schwartz, Nicolas Danchin, Michael Szarek et al.|Diabetes Care|2021Cited by 39